Related Experiment Videos
An extended experience with cefuroxime therapy of childhood bacterial meningitis
Insights
Cefuroxime is an effective and safe single antibiotic treatment for bacterial meningitis in children over one month old. This study found it led to prompt recovery in most patients, with favorable outcomes compared to other treatments.
Area of Science:
- Pediatric Infectious Diseases
- Bacteriology
- Clinical Pharmacology
Background:
- Bacterial meningitis remains a significant cause of childhood morbidity and mortality.
- Effective and safe single-drug therapies are crucial for managing pediatric bacterial meningitis.
- Cefuroxime, a second-generation cephalosporin, has shown broad-spectrum activity against common meningitis pathogens.
Purpose of the Study:
- To evaluate the efficacy and safety of cefuroxime as a single-drug therapy for bacterial meningitis in pediatric patients.
- To assess the clinical and bacteriological response to cefuroxime treatment.
- To compare the outcomes of cefuroxime therapy with existing data for other treatments.
Main Methods:
- Prospective evaluation of 84 pediatric patients with bacterial meningitis.
- Treatment with cefuroxime (200 mg/kg/day IV in four divided doses) for 9–13 days.
- Monitoring of clinical status, bacteriological response, fever, complications, and sequelae.
Main Results:
- 78 out of 84 patients (93%) were cured, with prompt clinical and bacteriological responses.
- Common pathogens included Haemophilus influenzae b, Neisseria meningitidis, and Streptococcus pneumoniae.
- All pathogens were susceptible in vitro to cefuroxime, including beta-lactamase producing H. influenzae.
- Favorable outcomes regarding fever, complications, and sequelae were observed compared to other studies.
Conclusions:
- Cefuroxime is an effective and safe single-drug therapy for bacterial meningitis in children beyond the neonatal period.
- The drug demonstrated prompt bacteriological and clinical efficacy.
- Outcomes in terms of fever, complications, and sequelae were comparable or superior to other treatment regimens.
Abstract:
Eighty-four pediatric patients with bacterial meningitis were prospectively evaluated while receiving cefuroxime (200 mg/kg/day in four equal intravenous doses) as single-drug therapy for 9 to 13 days. Six cases were admitted in extremis and died within a few hours because of irreversible central nervous system damage or shock. The remaining 78 patients were cured, and prompt bacteriological and clinical responses were noted. The pathogens were Haemophilus influenzae b (43 cases), Neisseria meningitidis (20 cases), Streptococcus pneumoniae (10 cases) and unknown (five cases). All pathogens were susceptible in vitro to cefuroxime including two strains of beta-lactamase producing H. influenzae. Time to defervescence, incidence and cause of both prolonged and secondary fever, as well as type and frequency of complications and sequelae compared favorably to other series. It is concluded that cefuroxime is effective and safe single-drug therapy for childhood bacterial meningitis beyond the neonatal age group.